WithdrawnNCT04454684
A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating disorders
Medication studyAges 21–65
Understand this study
Who could participate?
Listed age limits: 21 years to 65 years.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: February 2026
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Resilient Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT04454684
- Official title
Show the full official title
An Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Resilient Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including Midomafetamine.
Who can participate?
Listed age limits: 21 years to 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
